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Introduction: Impaired Quality of Life (QoL) in 
Congenital Adrenal Hyperplasia (CAH) has been 
demonstrated in adults, but research in children has 
yielded variable results. We investigated the impact of 
CAH on QoL of children and adolescents alongside clin-
ical health outcomes (biometric and biochemical profiles). 
Method: We collected data from 14 tertiary UK centres to 
explore current health status of 8-18 year olds with CAH. 
QoL was assessed by using three different questionnaires; 
strengths and difficulties questionnaire (SDQ), Paediatric 
Quality of life (PedsQL) and Self-image profile (SIP), the 
former two completed by both patients and their parents. 
Height, weight and blood pressure were converted to 
age and sex adjusted z-scores. Serum markers included 
17OH-progesterone (17OHP), androstenedione (D4), tes-
tosterone (T) and 11-ketotestosterone (11KT). Statistical 
Analysis: Statistical analysis comprised of principal com-
ponent analysis (PCA) followed by multivariate analysis 
of variance (MANOVA), and post hoc regression. Results: 
Of the 107 CAH patients included in the study, median 
age 12.4 years (IQR 10.0-15.1), 55% were female and 104 
completed at least 1 questionnaire. Adequate data for PCA 
was available from 73/107. Three Principal Components 
(PCs) with observed eigenvalues > 1 explained 71% of the 
total variance in the observed variables. PC1 reflected 
‘disease control’ comprising 17OHP, D4, T and 11KT. PC2 
reflected ‘biometrics’ comprising age, and height and weight 
z-score. PC3 reflected ‘blood pressure’, comprising systolic 
and diastolic z-score. PC1 correlated with outcomes in the 
parent and patient SDQ as well as parent PedsQL. PC2 
and PC3 did not correlate with QoL. Regression analysis 
revealed higher scores (indicating lower QoL) in the SDQ 
domain of emotional problems and PedsQL domain of emo-
tional health in patients where biomarkers suggested good 
control or overtreatment. Post hoc regression analysis re-
vealed a rise in Androstenedione of 10nmol/L equated to 
an improved SDQ emotional problems score of 0.5 points 
and an improved PedsQL emotional health score of 3 
points. Conclusion: The study found an interrelation 
between QoL and biomarkers of disease control in CAH. 
There were more emotional problems with higher levels of 
androgen suppression. Biochemical control within normal 
ranges did not predict emotional problems. However, unex-
pectedly, patients with very high levels of androgens were 
highlighted as reporting fewer problems with their emo-
tional QoL. Further research into QoL in CAH and optimal 
levels of biochemical control will further understanding.
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Background: We investigated iodine status and its as-
sociation with thyroid function among preschool children 
residing in iodine-sufficient area. Methods: From the 
Environment and Development of Children study, 477 chil-
dren were evaluated for thyroid function and urine iodine 
concentration (UIC) at age 6 during 2015-2017. After ex-
cluding children born with multiple birth and with con-
genital hypothyroidism or Hashimoto thyroiditis, 439 (231 
boys) were included. Subclinical hypothyroidism (SCH) 
was defined as thyroid stimulating hormone (TSH) levels 
between 4.9-10 μIU/mL with normal free T4 levels. Iodine 
status was evaluated by UIC and children were categorized 
into 4 groups: iodine deficient (UIC < 100 μg/L), adequate 
(UIC, 100-299  μg/L), mild excessive (UIC, 300-999  μg/L), 
severe excessive (UIC ≥ 1000 μg/L). Results: Goiter was 
palpated in 64 (14.6%) with female predominance (26.0% 
vs. 4.3%, P  <  0.001). Serum level of free T4 and T3 was 
1.2 ± 0.1 ng/dL and 148.1 ± 18.5 ng/dL, respectively. The 
median TSH level was 2.3 (0.53-8.59) μIU/mL and the 
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